pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing.

21. (Amended) The method of claim 1, wherein the disorder is a result of occupational or environmental exposure to smoke, an organic or inorganic dust, or an allergen.

22. (Amended) The method of claim 21, wherein the disorder is a result of occupational or environmental exposure to an organic or inorganic dust.

27. (Amended) The method of claim 26, wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting β_2 adrenergic agonists, and combinations thereof.

29. (Amended) A pharmaceutical formulation for pulmonary administration for treatment of an inflammatory respiratory disorder, comprising a first active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing, and a second active agent selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, and combinations thereof, and a carrier suitable for pulmonary drug administration.

30. (Amended) A dry powder pharmaceutical formulation for pulmonary administration, comprising an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and a carrier suitable for pulmonary drug administration.

Please **add** new claims 31-37 as indicated below.

31. (New) A pharmaceutical formulation for treatment of an inflammatory respiratory disorder, comprising a first active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing, and a second active agent selected from the group consisting of glucocorticoids, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

32. (New) The formulation of claim 31, wherein the formulation further comprises a carrier suitable for pulmonary drug administration, and the formulation is administered via inhalation.

33. (New) The formulation of claim 31, wherein the formulation is administered orally or parenterally.

34. (New) The formulation of claim 31, wherein the inflammatory respiratory disorder is selected from the group consisting of asthma, atopic asthma, non-atopic asthma, COPD, alveolitis and ILD.

35. (New) The dry powder formulation of claim 30, wherein the carrier is a pharmaceutical sugar.

36. (New) The dry powder formulation of claim 30, wherein the particles of the powder have a diameter from about 0.1 μm to about 65 μm.

37. (New) The formulation of claim 29, wherein the inflammatory respiratory disorder is selected from the group consisting of asthma, atopic asthma, non-atopic asthma, COPD, alveolitis and ILD.